Sign In
Buy VYNE
$0.656
-0.0200 (-2.96%)
At Close: Jun 03, 2026
Short Interest in VYNE Therapeutics Inc. (NASDAQ:VYNE) Decreases By 35.7%
02:19am, Wednesday, 15'th Apr 2026
VYNE Therapeutics Inc. (NASDAQ: VYNE - Get Free Report) was the recipient of a significant decrease in short interest in the month of March. As of March 31st, there was short interest totaling 121,535
Contrasting Vivani Medical (NASDAQ:VANI) & VYNE Therapeutics (NASDAQ:VYNE)
01:58am, Sunday, 15'th Mar 2026
VYNE Therapeutics (NASDAQ: VYNE - Get Free Report) and Vivani Medical (NASDAQ: VANI - Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two comp
VYNE Therapeutics Inc. (NASDAQ:VYNE) Short Interest Down 61.3% in February
02:55am, Wednesday, 11'th Mar 2026
VYNE Therapeutics Inc. (NASDAQ: VYNE - Get Free Report) was the target of a large drop in short interest in February. As of February 27th, there was short interest totaling 212,702 shares, a drop of 6
Shareholder Alert: The Ademi Firm investigates whether VYNE Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders
07:39pm, Thursday, 18'th Dec 2025
MILWAUKEE , Dec. 18, 2025 /PRNewswire/ -- The Ademi Firm is investigating VYNE (Nasdaq: VYNE) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of VYNE Therapeutics Inc. (NASDAQ: VYNE)
04:35pm, Wednesday, 17'th Dec 2025
NEW YORK , Dec. 17, 2025 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is
VYNE Therapeutics Inc. (VYNE) Yarrow Bioscience, Inc. - M&A Call Prepared Remarks Transcript
12:39pm, Wednesday, 17'th Dec 2025
VYNE Therapeutics Inc. (VYNE) Yarrow Bioscience, Inc. - M&A Call Prepared Remarks Transcript
VYNE Stock Alert: Halper Sadeh LLC is Investigating Whether the Merger of VYNE Therapeutics Inc. is Fair to Shareholders
12:30pm, Wednesday, 17'th Dec 2025
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of VYNE Therapeutics Inc. (NASDAQ: VYNE) and Yarrow Bioscience, Inc. is fair to VYNE share
VYNE Therapeutics and Yarrow Bioscience Announce Merger Agreement
08:00am, Wednesday, 17'th Dec 2025
NEW YORK, Dec. 17, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE”) and Yarrow Bioscience, Inc. (“Yarrow”) today announced that they have entered into a definitive merge
VYNE Therapeutics Inc. (VYNE) Reports Q3 Loss, Tops Revenue Estimates
10:16am, Thursday, 06'th Nov 2025
VYNE Therapeutics Inc. (VYNE) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.29 per share a year ago.
VYNE Therapeutics Reports 2025 Third Quarter Financial Results and Provides Business Update
08:00am, Thursday, 06'th Nov 2025
Company is progressing its previously initiated strategic review evaluating a range of options to maximize shareholder value, including assessment of internal pipeline opportunities and broader strate
Savara (NASDAQ:SVRA) vs. VYNE Therapeutics (NASDAQ:VYNE) Critical Comparison
02:48am, Sunday, 26'th Oct 2025
Savara (NASDAQ: SVRA - Get Free Report) and VYNE Therapeutics (NASDAQ: VYNE - Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two busines
VYNE Therapeutics Inc. (VYNE) Reports Q2 Loss, Lags Revenue Estimates
10:16am, Thursday, 14'th Aug 2025
VYNE Therapeutics Inc. (VYNE) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to a loss of $0.22 per share a year ago.
VYNE Therapeutics Reports 2025 Second Quarter Financial Results and Provides Business Update
08:00am, Thursday, 14'th Aug 2025
BRIDGEWATER, N.J., Aug. 14, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing different
VYNE Therapeutics Announces Topline Results from Phase 2b Trial with Repibresib Gel in Nonsegmental Vitiligo
08:00am, Wednesday, 30'th Jul 2025
Trial Did Not Meet Primary Endpoint or Key Secondary Endpoint of F-VASI50 and F-VASI75 Nominally Statistically Significant Effects Observed in Key Secondary and Exploratory Endpoints of Change from Ba
VYNE Therapeutics Provides Program Update on Oral BET inhibitor VYN202
07:45am, Wednesday, 02'nd Jul 2025
BRIDGEWATER, N.J., July 02, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing different
